Matinas Biopharma Holdings Inc (MTNB)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Matinas Biopharma Holdings Inc chart...

About the Company

matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec

CEO

Jerome Jabbour

Exchange

NYSE MKT LLC

Website

https://www.matinasbiopharma.com/

$0M

Total Revenue

29

Employees

$65M

Market Capitalization

-2.34

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MTNB News

Matinas BioPharma Holdings, Inc.

2mon ago, source: CNN

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...

Latest News for Matinas BioPharma Hldgs Stock (AMEX:MTNB)

21d ago, source: Benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session ...

Xeris Biopharma Holdings, Inc.

1mon ago, source: CNN

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products ...

Matinas BioPharma Holdings Inc

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Matinas BioPharma Holdings Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Matinas BioPharma Holdings Inc (MTNB)

11d ago, source: Investing

Investing.com - Matinas BioPharma (NYSE: MTNB) reported first quarter EPS of $-0.0259, better than the analyst estimate of $-0.0265. Revenue for the quarter came in at $1.03M ...

MTNB Matinas BioPharma Holdings, Inc.

1mon ago, source: Seeking Alpha

**NM signifies a non meaningful value. A dash signifies the data is not available.

Matinas BioPharma Holdings Inc.

20d ago, source: Wall Street Journal

1 Day MTNB 12.36% DJIA -0.16% Russell 2K 0.61% Health Care/Life Sciences -0.14% ...

Matinas BioPharma Holdings, Inc. (MTNB)

17d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...